T3期喉鳞状细胞癌保留方案中的喉食管功能无功能障碍生存期
Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma.
作者信息
Gorphe Philippe, Matias Margarida, Even Caroline, Ferte Charles, Bidault François, Garcia Gabriel, Temam Stéphane, Nguyen France, Blanchard Pierre, Tao Yungan, Janot François
机构信息
Department of Head and Neck Oncology, Gustave Roussy Institute, Villejuif, France
Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France.
出版信息
Anticancer Res. 2016 Dec;36(12):6625-6630. doi: 10.21873/anticanres.11269.
BACKGROUND
We reviewed the outcomes of patients with T3 laryngeal neoplasms with a fixed hemilarynx, a large gross tumor volume or a subglottic extension (SGE), treated with a laryngeal-preservation protocol with induction chemotherapy.
PATIENTS AND METHODS
The study end-points were laryngo-esophageal dysfunction-free survival (LEDFS), laryngectomy-free survival (LFS), overall survival (OS), and disease-free survival (DFS).
RESULTS
A total of 104 patients were included. The 2-year and 5-year OS rates were 70.4% and 54.5%, respectively. OS and DFS were independent of the treatment modality in the whole cohort (p=0.6546 and p=0.3006, respectively) and in patients with SGE (p=0.529 and p=0.255, respectively). The 2-year and 5-year LEDFS rates were 44.3% and 28.2%, respectively. LEDFS was not associated with initial hemilaryngeal fixation or SGE (p=0.5772 and p=0.0623, respectively).
CONCLUSION
Chemoselection is feasible without compromised oncological or functional outcomes in patients with an initially fixed hemilarynx or subglottic extension.
背景
我们回顾了采用诱导化疗的喉保留方案治疗的伴有半喉固定、大体肿瘤体积大或声门下扩展（SGE）的T3喉肿瘤患者的治疗结果。
患者与方法
研究终点为喉食管功能无异常生存期（LEDFS）、无喉切除术生存期（LFS）、总生存期（OS）和无病生存期（DFS）。
结果
共纳入104例患者。2年和5年总生存率分别为70.4%和54.5%。在整个队列中（分别为p = 0.6546和p = 0.3006）以及有声门下扩展的患者中（分别为p = 0.529和p = 0.255），总生存期和无病生存期与治疗方式无关。2年和5年喉食管功能无异常生存率分别为44.3%和28.2%。喉食管功能无异常生存期与初始半喉固定或声门下扩展无关（分别为p = 0.5772和p = 0.0623）。
结论
对于初始半喉固定或声门下扩展的患者，化疗选择是可行的，且不会影响肿瘤学或功能预后。
Zotero 插件